“…For example, patients undergoing systemic psoriasis treatments often face issues of access (eg, treatment expense, delays in obtaining insurance approvals to continue treatment or lack of insurance approval to increase the dose of treatment owing to suboptimal response, and difficulty in traveling to offices that provide psoriasis treatment) and tachyphylaxis, and often patients express safety concerns that result in treatment discontinuation. 3 In addition, prior treatment experience, which may inform response rates, may not be reflected in clinical trials (eg, the ACCEPT 4 …”